UNICOCELL BIOMED CO., LTD.
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
1. UNICOCELL BIOMED CO., LTD. Allogeneic Stem Cell Bank
2. Autologous Adipose-Derived Stem Cell Therapy Services
3. Patented Manufacturing Processes and Exclusive Applications
4. Mass Production Processes and CDMO Services
5. Patented Medical Device - Ultra-Low Temperature Biologics Storage Container, UnicoVial®
6. TAF ISO Certified Testing Services
(The content above was translated by AI.)
2. Autologous Adipose-Derived Stem Cell Therapy Services
3. Patented Manufacturing Processes and Exclusive Applications
4. Mass Production Processes and CDMO Services
5. Patented Medical Device - Ultra-Low Temperature Biologics Storage Container, UnicoVial®
6. TAF ISO Certified Testing Services
(The content above was translated by AI.)
Founded Year
2018
Unified Business No.
50753953
Status
Active
Number of Employees
30
Total Paid-in
Capital
636,370,000 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Innovation Board(2024)、Listing(2025)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Based on science, UNICOCELL BIOMED CO., LTD. excels in the research, development, and application of stem cell technology. The company aims to collaborate with domestic and international biomedical research and development institutions to jointly research and develop new stem cell drugs and stem cell technology applications. At the same time, it is expanding globally to develop cooperative channels and business partners, in order to promote the application of stem cell technology in regenerative medicine for the global aging society.
UNICOCELL BIOMED CO., LTD. has established a comprehensive allogeneic adipose-derived stem cell bank in accordance with the International Council for Harmonisation (ICH) guidelines, supplying clinical trial drugs and supporting other academic and research institutions in developing various indications. UNICOCELL BIOMED CO., LTD.'s new stem cell drug "ELIXCYTE®" is applied in the treatment of knee osteoarthritis and chronic kidney disease. Stem cell-derived technologies are also applied in the development of applications for retinal degenerative diseases and other regenerative medicine. UNICOCELL BIOMED CO., LTD.'s PIC/S GMP plant continuously advances quality improvement and process optimization, and develops mass production technologies, hoping to contribute to society through cell research and development.
(The content above was translated by AI.)
UNICOCELL BIOMED CO., LTD. has established a comprehensive allogeneic adipose-derived stem cell bank in accordance with the International Council for Harmonisation (ICH) guidelines, supplying clinical trial drugs and supporting other academic and research institutions in developing various indications. UNICOCELL BIOMED CO., LTD.'s new stem cell drug "ELIXCYTE®" is applied in the treatment of knee osteoarthritis and chronic kidney disease. Stem cell-derived technologies are also applied in the development of applications for retinal degenerative diseases and other regenerative medicine. UNICOCELL BIOMED CO., LTD.'s PIC/S GMP plant continuously advances quality improvement and process optimization, and develops mass production technologies, hoping to contribute to society through cell research and development.
(The content above was translated by AI.)
